Highly selective angiotensin II (Ang II) type 1 (AT 1 ) receptor blockers (ARBs) are now available.
Introduction
Angiotensin II (Ang II) is the major effector peptide of the renin-angiotensin system (RAS). Ang II binds to two receptor subtypes, Ang II type 1 and type 2 (AT 1 and AT 2 ) receptors, which are members of the G protein-coupled receptor superfamily (GPCRs). AT 1 receptor blockers (ARBs) are highly selective for the AT 1 receptor and block the deleterious effects of Ang II, such as vasoconstriction, aldosterone release, retention of sodium and water, sympathetic nerve activation and cell proliferation. 1 Many ARBs are available for clinical use worldwide. Most ARBs have class (or common) effects because they have common molecular structures (biphenyl-tetrazol and imidazol groups), 2 although recent clinical studies have demonstrated that not all ARBs have the same effects and some benefits conferred by ARBs may not be class effects, but rather molecular (or differential) effects. Each ARB has been shown to have molecular effects in basic experimental studies, and these effects may be due to small differences in the molecular structure of each ARB. The molecular effects are most likely caused by specific off-target effects. However, it is still controversial whether each ARB has molecular effects in a clinical setting. Therefore, this review focuses on the class effects versus molecular effects of ARBs in the field of translational research.
Structures of Ang II and AT 1 receptor
Ang II is an octapeptide that binds to AT 1 receptor, which contains 359 amino acids and has a molecular mass of 4 kDa, by four main unique interactions. Two salt bridges, one between the Ang II side-chain Arg 2 and the AT 1 residue Asp 281 and the other between Ang II a-COOH group of Phe 8 and the AT 1 residue Lys 199 , may be important for docking the hormone to the receptor. 3, 4 These salt-bridge interactions do not play a role in AT 1 receptor activation. In addition, we have shown that two important interactions, one between Phe 8 of Ang II and His 256 in AT 1 receptor 5 and the other between Ang II Tyr 4 and Asn 111 , are necessary to activate the receptor. 6, 7 Molecular structures of ARBs Seven kinds of ARBs are available for clinical use worldwide. Although several peptide types of ARBs have been synthesized since the 1970s, there have been problems with low bioavailability, short duration of action, and partial agonistic activity. The non-peptidergic ARB losartan was the first to be developed based on imidazole analogues, and was designed by computational modeling. 8 Various improved ARBs have been developed since losartan. For example, the chloride group of losartan was changed to a cyclopenthyl group to give irbesartan. Olmesartan contains a hydroxyl group in addition to an a-carboxyl group in the imidazole ring. Since ARBs mimic Ang II, most, including losartan, have common Binding affinities of ARBs The K d values of seven ARBs and Exp3174, which is an active metabolite of losartan, are shown in Figure 2 (our unpublished data). The K d values of AT 1 receptor binding were determined by 125 I-[Sar 1 , Ile 8 ]Ang II-binding experiments under equilibrium conditions, and binding kinetics values were determined. Irbesartan showed the lowest K d value, indicating that irbesartan may have the highest binding affinity to the AT 1 receptor among these eight ARBs. In particular, since irbesartan contains a cyclopentyl group instead of the chloride group in both losartan and Exp3174, irbesartan may show higher binding affinity than these two ARBs. Interestingly, the results of computational modeling have suggested that the cyclopentyl group of irbesartan may bind to a hydrophobic pocket in the AT 1 receptor (Figure 3 ). 9 In addition, since hydrophobic interaction may occur between the cyclopentyl group of irbesartan and the AT 1 receptor, using mutagenesis studies (our unpublished data), we refer to this interaction as 'pentagon attachment'. Thus, a small difference in the molecular structure may influence various binding affinities.
Fabia et al. studied 36 reports in which blood pressure (BP) was measured using ambulatory BP monitoring for at least 24 h. 10 The antihypertensive activities of ARBs differed, and the magnitude of the reduction in BP did not essentially depend on the initial BP values or on the dose used. In addition, the reduction in mean 24-h systolic BP with olmesartan was significantly greater than the reductions with losartan and valsartan, and equivalent to the reduction with irbesartan. 11 On the other hand, the magnitude of BP reduction was significantly greater for patients who received olmesartan, but not other ARBs including irbesartan, than for those who received enalapril. Thus, not all ARBs may have the same antihypertensive effects. Although it is natural that the results regarding binding affinities as a molecular effect were not always consistent with those regarding antihypertensive effects, olmesartan and irbesartan showed better binding affinities than the others, and these ARBs may also be better at lowering BP.
Receptor selectivity and insurmountability of ARBs
All ARBs expect for losartan are highly selective for the AT 1 receptor. In fact, ARBs show 10,000-30,000 times greater affinity for the AT 1 receptor than for the AT 2 receptor. This high selectivity Review SAGE Publications 2010 Los Angeles, London, New Delhi and Singapore implies that the AT 2 receptor may be exposed to a higher concentration of Ang II because of the renin-angiotensin feedback loop after ARB treatment. Although AT 2 receptor function is still unclear, Ang II-induced AT 2 receptor stimulation may cause anti-cell proliferation and vasodilation. 12 Surmountable and insurmountable antagonism largely correspond to competitive and non-competitive antagonism. Although losartan acted as a surmountable antagonist in isolated rat aorta, it acts like an insurmountable antagonist in other models. 13 All other ARBs are insurmountable antagonists. 14 In addition, compared with telmisartan, olmesartan showed a higher degree of insurmountability for the AT 1 receptor. 15 However, since insurmountable antagonists overcome the binding of antagonists to the AT 1 receptor only at a high plasma concentration of Ang II, this may not be relevant for the clinical application of ARBs.
Inverse agonism of ARBs
More than 60 wild-type (WT) GPCRs have been found to exhibit constitutive activity. 16 In most cases, significant levels of constitutive activity are seen in recombinant systems in which GPCR expression levels are relatively high. Although spontaneous mutations have not been reported for the AT 1 receptor, we reported that the WT AT 1 receptor shows slight but significant constitutive activity. 17 An inverse agonist can inhibit the constitutive activity of AT 1 receptor. We previously reported that olmesartan and valsartan are stronger inverse agonists than losartan against inositol phosphate production using constitutively active N111G AT 1 mutant receptor. 17, 18 Although the WT AT 1 receptor shows only slight constitutive activity, Morisset et al. clearly showed that inverse agonists are useful in a therapeutic strategy even if non-mutated receptors are expressed at normal levels in GPCRs, such as the H 3 receptor. 19 AT 1 receptor mRNA levels were upregulated by myocyte stretching over time; significant increases were evident 6 h after stretching, maximal levels (2.8-fold) were observed at 12 h, and these effects were sustained for up to 18 h. 20 In addition, a recent study demonstrated that the AT 1 receptor is activated by the mechanical stretching of cultured rat myocytes 21, 22 and constriction of the transverse aorta in angiotensinogen knockout mice 21 without the involvement of Ang II, and these adverse effects were suppressed by an inverse agonist. Candesartan had greater effects than losartan. In this way, an inverse agonist for the AT 1 receptor may have pharmacotherapeutic relevance, as a molecular effect, for preventing progression of the disease because it can take several decades for hypertension to progress to cardiovascular disease. 23 Several clinical trials have evaluated the effects of ARBs on morbidity and mortality in patients with heart failure (HF). The ELITE II trial suggested that treatment with losartan is not superior to treatment with captopril. 24 In the CHARM trial, the benefits of candesartan were demonstrated in patients with HF. 25 Although there are important differences in the design and hypotheses of these trials that must be taken into account when comparing their results and interpreting their clinical impact, we should also consider whether these are class effects of ARBs. The inverse agonistic activity of ARBs might also be important for their efficacy in the long-term treatment of heart disease such as HF, including cardiac remodeling, independent of blood pressure-lowering. Although most ARBs have been simply classified as antagonists, it may important to classify ARBs with regard to their capacity for inverse agonism as a molecular effect.
Anti-inflammatory effects of ARBs
Ang II induces inflammation in vasculature and vascular remodeling, and subsequently promotes atherosclerosis. Ang II stimulates monocyte chemoattractant protein-1 (MCP-1), 26 interleukin (IL)-8, tumor necrosis factor-a and IL-6 production. Irbesartan inhibited basal MCP-1 production in a dose-dependent manner in human monocytes. 27 A similar effect was seen with losartan, at concentrations that were twice as high as those with irbesartan. These studies also showed that irbesartan decreased basal MCP-1 levels, possibly through a mechanism that was independent of binding to the AT 1 receptor.
The adipose-specific protein adiponectin has been recently discovered to improve insulin sensitivity and inhibit inflammation. Adiponectin protein expression was markedly stimulated by Ang II, which was inhibited by blockade of the AT 2 receptor, and further enhanced by irbesartan. 28 Irbesartan-mediated upregulation of adiponectin started beyond the concentrations needed for AT 1 receptor blockade and was also present in the absence of Ang II, which suggests that an AT 1 receptor-independent mechanism of action may be involved. Telmisartan also stimulated adiponectin protein expression, whereas the nonperoxisome proliferator-activated receptor (PPAR) g-activating eprosartan had no effect. ARBs have molecular effects against MCP-1 production and PPARg activation, and these effects may not be mediated by AT 1 receptor. There may be another membrane receptor for the irbesartan-induced inhibition of MCP-1 production. Interestingly, both irbesartan and olmesartan may act as antagonists of a theoretical molecular model of C-Chemokine receptor, type-2b. 29 Clinical studies have demonstrated that some ARBs decrease the incidence of new-onset type 2 diabetes. 30 In addition, losartan and candesartan increase the plasma levels of adiponectin in patients with essential hypertension. 31, 32 Although some ARBs have been shown to activate PPARg, the concentrations used were very high, 33, 34 and it is doubtful that such concentrations can be achieved in humans. Future large prospective clinical studies that compare PPARg-activating ARBs with non-activating ARBs will be required to clearly show that a PPARg-activating phenotype in ARB is superior in patients with type 2 diabetes mellitus and/or hypertension.
Reduction of serum uric acid by ARBs
Generally, ARBs decrease microalbuminuria and proteinuria. With regard to organ protection in the kidney, irbesartan has been studied in two critical large-scale clinical trials: IDNT (Irbesartan Diabetic Nephropathy Trial) 34 and IRMA2 (Irbesartan in patients with type 2 diabetes and microalbuminuria). 35 Irbesartan is effective for protecting against the progression of nephropathy due to type 2 diabetes independent of the reduction in BP, 35 and has been shown to have a renoprotective effect independent of its BP-lowering effect in patients with type 2 diabetes and microalbuminuria. 36 Although the anti-inflammatory effect of irbesartan was stronger than that of losartan, losartan has also been the subject of an important large-scale clinical trial, called RENAAL. 37 In that study, losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and although molecular effects did not influence the clinical outcome directly, losartan may have another important molecular effect. Serum uric acid (sUA) is currently recognized as Review SAGE Publications 2010 Los Angeles, London, New Delhi and Singapore a risk factor for cardiovascular disease as well as chronic kidney disease. Compared with other ARBs, both losartan and irbesartan have been shown to reduce sUA. Interestingly, losartan and telmisartan exhibited cis-inhibitory effects on the uptake of UA by the renal UA transporter (URAT1), and these ARBs reduced uptake in competitive inhibition kinetics. 38 On the other hand, candesartan, Exp3174 (a major metabolite of losartan), olmesartan and valsartan did not have similar inhibitory effects. Such differences in the effects of ARBs on URAT1 could be predicted from the partial chemical structures of ARBs and may involve an AT 1 receptor-independent mechanism of action. The molecular effects of each ARB may be associated with differences in the strength and weakness of the effect of the ARB, and may not reflect the clinical outcome.
Direct comparison of the efficacies on ARBs in clinical trials
Over the past decade, the efficacies of ARBs have been compared and differences were observed, as shown in Table 1 , except with regard to lowering of BP. For example, valsartan is more effective than losartan at reducing left ventricular mass index in hypertensive patients, 39 and induces greater renal NO production than losartan in hypertensive patients with chronic renal disease. 40 Candesartan, but not losartan, significantly lowered plasma levels of plasminogen activator inhibitor type-1 antigen and MCP-1 in patients with hypertension. 41 Exp 3174 is the most efficacious ARB at preventing human coronary artery contraction. 42 Valsartan decreased the rate of target lesion revascularization after stenting compared with losartan. 43 Olmesartan showed a significant reduction of high-sensitive C-reactive protein after stenting compared with valsartan. 44 Changes in serum adiponectin and plasma glucose were significantly greater in the telmisartan group than in the candesartan group in patients with both type 2 diabetes and hypertension. 45 Although losartan is numerically inferior in comparison with other ARBs with regard to lowering of BP, losartan produced a significantly greater reduction in human platelet activation than did valsartan and candesartan. 46 These differences in the effects of ARBs are independent of lowering of BP in most studies.
When olmesartan was compared with telmisartan, conflicting data were reported. 47, 48 Although there were no differences between olmesartan and telmisartan with regard to their effects on metabolic parameters, including hemoglobinA1c and adiponectin, the decreases in serum IL-6 and hsCRP were more significant with olmesartan. 47 On the other hand, telmisartan was more beneficial than olmesartan for improving glucose and lipid profiles. 48 Since these trials were relatively small, we must be careful when comparing their results and interpreting their clinical impact, and should also reconsider whether these are molecular effects of ARBs, rather than class effects.
Conclusions
Several clinical trials have shown that ARBs have different degrees of beneficial effects. While most of the benefits conferred by ARBs may be class effects, some may be due to molecular effects. Basic research has clearly demonstrated some molecular effects of ARBs, and an exciting new area in ARB treatment is to determine whether these basic findings can influence the clinical outcome directly or indirectly. 
